[CLSTR]
< Back to situation

[REVISION HISTORY]

Biologic therapy analysis and new HS management guidelines

Updated 2 times since CLSTR started tracking revisions of this situation.

What changed

2026-10-12 02:29 UTC → 2026-10-21 14:06 UTC · added removed

Biologic therapy analysis for hidradenitis suppurativa and new HS management guidelines

Recent medical analyses have evaluated the comparative effectiveness and cost-efficiency of biologic therapies for moderate-to-severe hidradenitis suppurativa (HS), specifically focusing on adalimumab, secukinumab, and bimekizumab. An international economic evaluation published in JAMA Dermatology found that adalimumab provided the most favorable balance between acquisition cost and clinical efficacy across healthcare systems in the US, Canada, France, Germany, and Australia. several countries. Subsequent research in the Journal of the European Academy of Dermatology and Venereology indicated that bimekizumab showed higher odds of clinical response and greater quality-of-life improvements compared to secukinumab and adalimumab, though these results were not from direct head-to-head trials. At the 2026 Fall Clinical Dermatology Conference, medical experts Iltefat Hamzavi, MD, and Jennifer Hsiao, MD, emphasized a comprehensive management approach. This strategy extends beyond medication to include approach involving structured symptom assessment using patient-reported data, assessment, wound care, and screening for comorbidities such as like inflammatory bowel disease and spondyloarthritis. disease. While adalimumab, secukinumab, and bimekizumab remain the three are FDA-approved biologics for moderate-to-severe HS, pharmacological options may expand. The biologics, the oral Janus kinase (JAK) JAK inhibitor povorcitinib is currently remains under FDA review following phase 3 trials that demonstrated review. In a significant development, the American Academy of Dermatology (AAD) and the Hidradenitis Suppurativa Foundation (HSF) released the first joint clinical response rates. guidelines for HS management. Published in the Journal of the American Academy of Dermatology, the guidelines offer 37 evidence-based recommendations for patients aged nine and older. For moderate-to-severe cases, the guidelines issue a strong recommendation for biologic therapies, including adalimumab, bimekizumab, infliximab, and secukinumab, to reduce abscesses and nodules. Notably, the guidelines identify step therapy—an insurance practice requiring specific designated treatments before accessing preferred medications—as a primary barrier to care, noting it lacks evidence of clinical benefit and is linked to treatment delays and poorer outcomes.

Versions

  1. 2026-10-21 14:06 UTC Biologic therapy analysis and new HS management guidelines
  2. 2026-10-12 02:29 UTC Biologic therapy analysis for hidradenitis suppurativa
  3. 2026-10-09 00:54 UTC Biologic therapy analysis for hidradenitis suppurativa

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.